高级检索
    杨辞秋, 王坤, 陈媛琪. 帕博利珠单抗联合化疗应用于早期三阴性乳腺癌新辅助治疗中的首个前瞻性随机对照Ⅲ期临床研究[J]. 循证医学, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
    引用本文: 杨辞秋, 王坤, 陈媛琪. 帕博利珠单抗联合化疗应用于早期三阴性乳腺癌新辅助治疗中的首个前瞻性随机对照Ⅲ期临床研究[J]. 循证医学, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
    shu
    YANG Ci-qiu, WANG Kun, CHEN Yuan-qi. The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
    Citation: YANG Ci-qiu, WANG Kun, CHEN Yuan-qi. The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
    shu

    帕博利珠单抗联合化疗应用于早期三阴性乳腺癌新辅助治疗中的首个前瞻性随机对照Ⅲ期临床研究

    The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回